YOLFTbeta
Aligned Genetics Inc

Aligned Genetics Inc

238120 · KQ · Healthcare / Medical Devices

2,790.00KRW-5.00 (-0.18%)

Price History

Full chart

Market Stats

Previous Close2,795.00
Open2,800.00
Day Range2,770.00 – 2,835.00
52-Week Range2,380.00 – 6,050.00
Volume7.30K
Market Cap38.69B
P/E (TTM)0.00
Forward P/E0.00
Dividend Yield0.00%
Beta0.49
50-Day Avg2,972.90
200-Day Avg3,682.23

About

Aligned Genetics, Inc. offers cellular imaging and biomolecular analysis solutions worldwide. It also provides molecular diagnostic solutions for rapid results under the Genescale name; and advanced imaging and analysis solutions under the Logos Biosystems name. The company was formerly known as Logos Biosystems, Inc. and changed its name to Aligned Genetics, Inc. in September 2020. Aligned Genetics, Inc. was founded in 2008 and is headquartered in Anyang-Si, South Korea.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Yeon-Cheol Jung
  • Employees66
  • Headquarters28 Simindaero, Anyang-Si, South Korea, 14055, Korea
  • Websitehttps://alignedgenetics.com

Leadership

  • Mr. Yeon-Cheol JungChief Executive Officer · b. 1970
  • Mr. Keun-Chang ChoDirector of Research and Director · b. 1968
  • Mr. Byong-Seung ChoDirector of Planning and Director · b. 1972
  • Mr. Yeon-Seok JungDirector of Management and Director · b. 1973
  • Mr. Sung-Cheol ParkExecutive Director of Business Consulting and Director · b. 1964
  • Mr. Nu-Ri JeonDirector of Business Consulting and Director · b. 1969

Financials

Income Statement

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue4.10B4.71B5.64B5.68B7.79B7.96B11.76B13.75B15.21B15.78B16.02B
Growth (%)-+15.04%+19.62%+0.69%+37.33%+2.10%+47.82%+16.92%+10.63%+3.70%+1.51%
Cost of Revenue1.44B2.19B2.04B2.32B3.18B3.41B4.42B4.99B4.54B4.62B4.79B
Gross Profit2.66B2.52B3.60B3.36B4.61B4.54B7.35B8.77B10.67B11.16B11.23B
Gross Margin64.84%53.47%63.86%59.14%59.18%57.09%62.46%63.74%70.13%70.70%70.10%
Operating Expense3.03B4.19B5.45B5.28B5.01B4.80B5.17B5.92B7.33B8.38B8.78B
Operating Income-373.52M-1.67B-1.85B-1.92B-398.92M-253.48M2.18B2.85B3.34B2.78B2.44B
Operating Margin-9.12%-35.51%-32.78%-33.90%-5.12%-3.19%18.53%20.72%21.93%17.62%15.25%
EBITDA-------3.26B4.27B5.29B3.36B
EBITDA Margin-------23.69%28.07%33.51%20.99%
Net Income-261.36M-1.56B-1.75B-1.59B116.74M468.23M5.54B2.33B3.24B4.13B2.91B
Net Income Margin-6.38%-33.02%-31.13%-27.98%1.50%5.88%47.12%16.96%21.27%26.16%18.18%
R&D587.01M578.06M940.40M1.16B884.80M816.17M943.58M1.08B1.68B2.29B2.02B
R&D as % of Total Revenue14.33%12.27%16.69%20.36%11.35%10.26%8.02%7.85%11.07%14.53%12.59%
Interest Expense0000118.64M82.83M28.88M165.96M214.88M169.15M103.88M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%1.52%1.04%0.25%1.21%1.41%1.07%0.65%

Balance Sheet

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets6.86B25.86B24.31B23.00B24.62B25.48B34.47B36.90B40.93B44.28B57.79B
Total Liabilities796.04M1.68B1.67B2.11B3.65B4.02B7.48B8.05B9.62B8.78B20.63B
Total Equity6.06B24.18B22.64B20.89B20.97B21.46B26.99B28.85B31.31B35.49B37.16B
Cash3.24B9.31B7.41B2.87B4.90B5.64B5.28B9.44B14.93B8.33B14.62B
Total Debt----994.02M916.77M-----

Cash Flow

Currency: KRW2015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-351.72M-1.14B-876.75M-1.75B659.29M35.67M135.97M2.22B2.85B3.07B3.61B
Investing Cash Flow500.62M-12.82B-1.08B-2.92B1.53B1.17B-3.67B2.54B1.29B-7.55B-
Financing Cash Flow20.02B20.02B164.34M-203.84M-203.84M-227.56M3.63B-176.33M-192.75M-1.73B-
Capital Expenditure424.84M864.92M405.44M213.35M261.62M96.43M3.31B2.00B880.42M340.06M12.91B
Free Cash Flow----133.53M-69.84M-4.73B218.75M1.97B2.66B-9.30B
FCF to OCF----20.25%-195.78%-3477.41%9.84%69.09%86.84%-257.99%

Earnings

Report DateMay 15, 2017Aug 14, 2017Nov 14, 2017Mar 20, 2018May 15, 2018Aug 14, 2018Nov 14, 2018Mar 19, 2019Mar 31, 2019Jun 30, 2019Sep 30, 2019Dec 31, 2019Mar 31, 2020Jun 30, 2020Sep 30, 2020Dec 31, 2020Mar 31, 2021Jun 30, 2021Sep 30, 2021Dec 31, 2021Mar 31, 2022Aug 16, 2022Nov 14, 2022Jan 25, 2023Mar 31, 2023Jun 30, 2023Sep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
EPS Estimate--------------------------------------
EPS Actual-73.30-46.13-17.17-108.39-90.22-34.79-58.37-37.52-5.16-6.9911.658.6312.83-26.02-3.0448.79109.2877.0340.84158.2544.5894.00244.00-102.6129.2752.0293.4550.3143.6043.1835.27165.0438.81-8.3366.37109.6629.70124.45
Surprise--------------------------------------
TimingPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-marketPre-market-------------Pre-marketAfter-hoursPre-market--------------

Key Statistics & Ratios

Market Cap38.69B
Enterprise Value41.55B
Trailing P/E0.00
Forward P/E0.00
Price / Sales2.39
Price / Book1.07
Revenue (TTM)16.16B
Gross Profit (TTM)11.87B
EBITDA3.22B
Profit Margin28.72%
Operating Margin14.81%
Return on Equity12.56%
Return on Assets3.04%
Shares Outstanding14.17M
Shares Float6.78M
Beta0.49
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 7, 20232:1
  • Jul 20, 20202:1